InvesTrust Acquires New Holdings in GSK plc (NYSE:GSK)

InvesTrust bought a new position in GSK plc (NYSE:GSK) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 101,298 shares of the pharmaceutical company’s stock, valued at approximately $3,422,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sunbelt Securities Inc. boosted its position in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 303 shares during the period. Mesirow Financial Investment Management Inc. boosted its holdings in shares of GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after buying an additional 323 shares in the last quarter. Rehmann Capital Advisory Group grew its position in shares of GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares during the period. Finally, Investment Partners Asset Management Inc. increased its stake in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Down 0.6 %

GSK stock traded down $0.19 during midday trading on Wednesday, hitting $33.90. The company’s stock had a trading volume of 1,448,735 shares, compared to its average volume of 2,534,150. The firm’s 50-day moving average is $34.59 and its 200-day moving average is $38.30. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a market cap of $70.26 billion, a PE ratio of 22.01, a P/E/G ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. GSK’s dividend payout ratio (DPR) is 98.70%.

Analysts Set New Price Targets

GSK has been the topic of a number of recent research reports. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.